|
Real-time Estimate
Tradegate
22:51:34 27/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 61.95 EUR | +0.90% |
|
+5.37% | -2.60% |
| 10-05 | Spanish stocks - Factors to watch on Oct 5 | RE |
| 07-23 | Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026 |
Company Valuation: Laboratorios Farmaceuticos Rovi, S.A.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 4,138 | 1,925 | 3,213 | 3,220 | 3,248 | 3,140 | - | - |
| Change | - | -53.49% | 66.93% | 0.22% | 0.87% | -3.32% | - | - |
| Enterprise Value (EV) 1 | 4,112 | 1,872 | 3,251 | 3,305 | 3,272 | 3,135 | 3,077 | 2,964 |
| Change | - | -54.48% | 73.7% | 1.65% | -1% | -4.17% | -1.88% | -3.66% |
| P/E | 26.7x | 9.67x | 18.8x | 23.6x | 23.1x | 19.4x | 18.6x | 15.4x |
| PBR | 8.59x | 3.71x | 5.94x | 5.63x | 4.89x | 4.03x | 3.53x | 3.04x |
| PEG | - | 0.3x | -1.3x | -1.4x | 7.71x | 1.3x | 4.31x | 0.8x |
| Capitalization / Revenue | 6.38x | 2.35x | 3.87x | 4.22x | 4.37x | 4.02x | 3.5x | 3.24x |
| EV / Revenue | 6.34x | 2.29x | 3.92x | 4.33x | 4.4x | 4.02x | 3.43x | 3.06x |
| EV / EBITDA | 20.3x | 6.72x | 13.3x | 15.9x | 15.1x | 15.2x | 12.1x | 9.84x |
| EV / EBIT | 22.7x | 7.32x | 14.8x | 18.4x | 17.6x | 18x | 14.1x | 11.2x |
| EV / FCF | 37.9x | 10.1x | 54.3x | 43.5x | 27.4x | 30.1x | 25.5x | 18.2x |
| FCF Yield | 2.64% | 9.95% | 1.84% | 2.3% | 3.65% | 3.32% | 3.92% | 5.48% |
| Dividend per Share 2 | 0.9556 | 1.294 | 1.104 | 0.9351 | 0.9594 | 0.9584 | 1.174 | 1.281 |
| Rate of return | 1.29% | 3.59% | 1.83% | 1.49% | 1.51% | 1.56% | 1.91% | 2.09% |
| EPS 2 | 2.76 | 3.73 | 3.2 | 2.67 | 2.75 | 3.165 | 3.302 | 3.975 |
| Distribution rate | 34.6% | 34.7% | 34.5% | 35% | 34.9% | 30.3% | 35.6% | 32.2% |
| Net sales 1 | 648.7 | 817.7 | 829.5 | 763.7 | 743.5 | 780.3 | 896 | 969 |
| EBITDA 1 | 202.9 | 278.7 | 244.5 | 207.4 | 216.2 | 206.9 | 254.1 | 301.1 |
| EBIT 1 | 181.5 | 255.8 | 220.1 | 179.4 | 185.8 | 173.7 | 218.2 | 263.7 |
| Net income 1 | 153.1 | 199.7 | 170.3 | 136.9 | 140.4 | 146.7 | 169.4 | 203.3 |
| Net Debt 1 | -25.87 | -52.78 | 38.6 | 85.1 | 23.84 | -4.785 | -63.65 | -176.4 |
| Reference price 2 | 73.80 | 36.06 | 60.20 | 62.95 | 63.50 | 61.40 | 61.40 | 61.40 |
| Nbr of stocks (in thousands) | 56,069 | 53,375 | 53,370 | 51,149 | 51,149 | 51,143 | - | - |
| Announcement Date | 23/2/22 | 21/2/23 | 27/2/24 | 25/2/25 | 24/2/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 19.4x | 4.02x | 15.15x | 1.56% | 3.51B | |
| 37.58x | 13.15x | 27.92x | 0.53% | 1,140B | |
| 38.98x | 6.55x | 18.43x | 2% | 641B | |
| 37.5x | 8.41x | 17.39x | 2.4% | 507B | |
| 21.33x | 5.19x | 12.91x | 2.53% | 383B | |
| 102.5x | 5.75x | 24.67x | 2.42% | 347B | |
| 21.61x | 5.64x | 13.85x | 2.84% | 293B | |
| 22.44x | 4.53x | 12.94x | 1.95% | 266B | |
| 28.21x | 7.23x | 12.94x | 2.27% | 240B | |
| -46.25x | 7.08x | 27.47x | 2.08% | 197B | |
| Average | 28.33x | 6.76x | 18.37x | 2.06% | 401.73B | |
| Weighted average by Cap. | 35.00x | 8.32x | 20.42x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ROVI Stock
- Valuation Laboratorios Farmaceuticos Rovi, S.A.
Select your edition
All financial news and data tailored to specific country editions
